Sinopharm Group Co Stock Debt To Equity
| SHTDFDelisted Stock | USD 2.70 0.00 0.00% |
Sinopharm Group Co fundamentals help investors to digest information that contributes to Sinopharm Group's financial success or failures. It also enables traders to predict the movement of Sinopharm Pink Sheet. The fundamental analysis module provides a way to measure Sinopharm Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sinopharm Group pink sheet.
Sinopharm |
Sinopharm Group Co Company Debt To Equity Analysis
Sinopharm Group's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Sinopharm Group Debt To Equity | 0.89 % |
Most of Sinopharm Group's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinopharm Group Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Sinopharm Group Co has a Debt To Equity of 0.894%. This is 98.33% lower than that of the Healthcare sector and 99.35% lower than that of the Medical Distribution industry. The debt to equity for all United States stocks is 98.16% higher than that of the company.
Sinopharm Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinopharm Group's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sinopharm Group could also be used in its relative valuation, which is a method of valuing Sinopharm Group by comparing valuation metrics of similar companies.Sinopharm Group is currently under evaluation in debt to equity category among its peers.
Sinopharm Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 16.78 B | |||
| Shares Outstanding | 1.34 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 51.07 % | |||
| Price To Earning | 5.67 X | |||
| Price To Book | 0.88 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 521.05 B | |||
| Gross Profit | 44.05 B | |||
| EBITDA | 20.76 B | |||
| Net Income | 7.76 B | |||
| Cash And Equivalents | 32.15 B | |||
| Cash Per Share | 10.30 X | |||
| Total Debt | 8.42 B | |||
| Debt To Equity | 0.89 % | |||
| Current Ratio | 1.31 X | |||
| Book Value Per Share | 21.01 X | |||
| Cash Flow From Operations | 9.31 B | |||
| Earnings Per Share | 0.37 X | |||
| Price To Earnings To Growth | 49.02 X | |||
| Number Of Employees | 113.23 K | |||
| Beta | 0.72 | |||
| Market Capitalization | 8.94 B | |||
| Total Asset | 335.41 B | |||
| Retained Earnings | 11.43 B | |||
| Working Capital | 32.26 B | |||
| Current Asset | 130.51 B | |||
| Current Liabilities | 98.25 B | |||
| Z Score | 1.6 | |||
| Annual Yield | 0.05 % | |||
| Five Year Return | 3.09 % | |||
| Net Asset | 335.41 B | |||
| Last Dividend Paid | 0.75 |
About Sinopharm Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sinopharm Group Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinopharm Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinopharm Group Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Sinopharm Pink Sheet
If you are still planning to invest in Sinopharm Group check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinopharm Group's history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |